Asia-Pacific Oligonucleotides Synthesis Market Outlook to 2028

Asia-Pacific Oligonucleotides Synthesis Market Overview

The Asia-Pacific Oligonucleotides Synthesis Market is valued at USD 2.3 billion, driven by the rapid adoption of nucleic acid-based therapeutics, including m RNA vaccines and gene therapies. This growth has been fueled by increasing demand from the biotechnology and pharmaceutical industries, particularly for research and development of innovative drugs. Oligonucleotides are essential in gene synthesis, DNA sequencing, and gene editing technologies, which are driving expansion across the region.

Countries like China, Japan, and India dominate the market due to their strong biopharmaceutical infrastructure and investments in research. China, for instance, leads in oligonucleotide manufacturing due to a highly skilled workforce and government initiatives promoting the biotech sector. Japans long-standing reputation in pharmaceutical innovation also positions it as a significant market player.

Oligo Factory has achieved Good Manufacturing Practices (GMP) compliance, particularly aligning with ICHQ7 guidelines. This initiative emphasizes their commitment to high-quality production for oligonucleotides, supporting pharmaceutical and biotechnology applications such as drug discovery and diagnostics. By enhancing documentation, traceability, and implementing regular audits, Oligo Factory can now ensure more consistent production standards. The new facility opened in 2023 significantly boosts their synthesis capacity, allowing them to meet growing industry demand.

Asia-Pacific Oligonucleotides Synthesis Market Segmentation

By Product Type: The Asia-Pacific Oligonucleotides Synthesis market is segmented by product type into custom oligonucleotides, primers and probes, and therapeutic oligonucleotides. Therapeutic oligonucleotides hold a dominant market share under this segmentation due to their extensive application in m RNA vaccines and gene therapy solutions. These oligonucleotides are vital for developing treatments for genetic disorders, cancer, and viral infections. The rising adoption of these therapies, particularly in China and Japan, has significantly contributed to this segment's growth.

By Application: The Asia-Pacific Oligonucleotides Synthesis market is segmented by application into research, diagnostics, and therapeutics. Therapeutics lead this segmentation due to the ongoing research and clinical trials involving oligonucleotide-based drugs, especially in gene editing and cancer therapy. Many pharmaceutical companies are increasingly utilizing oligonucleotides in precision medicine, making the therapeutics sub-segment the largest within this market.

Asia-Pacific Oligonucleotides Synthesis Market Competitive Landscape

The market is dominated by both regional and international players. Key players in the region include companies that specialize in custom synthesis services, research applications, and therapeutics. The market is highly competitive, with many companies focusing on R&D, mergers and acquisitions, and collaborations to maintain their market presence. The Asia-Pacific market is heavily influenced by these major players, which are driving innovation in oligonucleotide synthesis through constant R&D and strategic collaborations.

Company Name

Establishment Year

Headquarters

No. of Employees

Revenue (2023)

R&D Investment

Key Product Offering

Market Penetration

Strategic Collaborations

Agilent Technologies

1999

USA

Gen Script Biotech Corp

2002

China

Thermo Fisher Scientific

1956

USA

Eurofins Genomics

1987

Germany

Twist Bioscience

2013

USA

Asia-Pacific Oligonucleotides Synthesis Industry Analysis

Growth Drivers

Growing Demand for Nucleic Acid-Based Therapies (m RNA vaccines, Gene Therapy): The press release include the development of an indigenous m RNA-based platform for vaccine manufacturing, supported by the Indian government through initiatives like Mission COVID Suraksha. This platform was pivotal in developing vaccines such as GEMCOVAC-OM, which does not require ultra-cold chain infrastructure, easing deployment. Strategic funding from the Department of Biotechnology (DBT) also played a significant role in fostering technological innovation and rapid vaccine development.

Advancements in Therapeutics and Diagnostics (Precision Medicine, Gene Editing): The advancements in therapeutics and diagnostics are significantly boosting the oligonucleotide synthesis market in the Asia-Pacific region. With increasing precision medicine applications, gene editing techniques such as CRISPR have gained considerable momentum. In December 2023, Moderna Therapeutics launched a groundbreaking oligonucleotide synthesis technology, revolutionizing m RNA-based therapeutics production.

Rising Applications in Biotechnology and Pharmaceutical Industries: Oligonucleotides are becoming integral to biotechnology and pharmaceutical industries due to their wide applications in drug discovery, diagnostics, and synthetic biology. The growing number of biopharmaceutical companies in Asia-Pacific, especially in countries like China, Japan, and India, is driving the demand for oligonucleotide synthesis. This trend is supported by the expansion of biotechnology firms that focus on areas like gene therapy, personalized medicine, and synthetic biology, where oligonucleotides play a crucial role in developing next-generation treatments.

Market Challenges

High Production Costs of Oligonucleotides (Custom Synthesis, Large-Scale Manufacturing): Manufacturing oligonucleotides, especially for custom and large-scale production, presents significant cost challenges for companies. The high cost of essential raw materials and the requirement to adhere to stringent manufacturing standards, such as Good Manufacturing Practice (GMP), add to the expense. Additionally, setting up large-scale production facilities involves substantial financial investments, making it difficult for smaller firms to compete in the market.

Complex Regulatory Frameworks (GMP, ICH Guidelines): Navigating the regulatory environment in the Asia-Pacific region is challenging for oligonucleotide manufacturers. Regulatory bodies in countries like China, India, and Japan enforce stringent compliance guidelines, including GMP and ICH standards. These regulations can slow down product approvals and increase the cost of compliance, making it difficult for companies to swiftly bring products to market.

Asia-Pacific Oligonucleotides Synthesis Market Future Outlook

Over the next five years, the Asia-Pacific Oligonucleotides Synthesis market is expected to experience significant growth driven by advancements in gene editing technologies, increasing demand for precision medicine, and rising investment in biotechnology. The region's robust pharmaceutical industry and increasing government support for biotech innovation will further propel the market.

Market Opportunities

Expansion into Emerging Markets (China, India): The oligonucleotide synthesis market in the Asia-Pacific region is experiencing growth, particularly in emerging markets such as China and India. Both countries are rapidly expanding their biotechnology and pharmaceutical industries, offering significant opportunities for oligonucleotide manufacturers. Government initiatives in China and India are encouraging local biotech production and innovation, which is driving increased demand for oligonucleotides in applications like drug discovery, diagnostics, and genetic research.

Integration of AI and Machine Learning in Drug Discovery: Artificial intelligence (AI) and machine learning (ML) are revolutionizing drug discovery, creating new opportunities for oligonucleotide synthesis. AI-driven platforms are helping optimize the design and development processes, reducing time and costs in the research of oligonucleotide-based therapeutics. The integration of these technologies is also fostering partnerships between biotechnology firms and AI developers, further accelerating innovation in drug development and driving demand for custom oligonucleotide synthesis services.
Please Note: It will take 5-7 business days to complete the report upon order confirmation